Welcome to our dedicated page for Neuraxis news (Ticker: NRXS), a resource for investors and traders seeking the latest updates and insights on Neuraxis stock.
NeurAxis, Inc. commercializes neuromodulation therapies for chronic and debilitating conditions in children and adults. The company’s proprietary IB-Stim product uses Percutaneous Electrical Nerve Field Stimulation, or PENFS, and is FDA cleared for functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and FD-related nausea symptoms in patients 8 years and older.
Recurring NeurAxis news includes FDA clearance updates, reimbursement and coding developments, medical policy coverage decisions, commercial access through payer and government channels, and adoption of PENFS in clinical practice. Company updates also cover quarterly financial results, business update calls, preferred stock dividends, equity and balance-sheet activity, and changes involving licensed neuromodulation assets.
NeurAxis (NYSE American: NRXS) reported record Q1 2026 revenue of $1.6 million, up 80% year over year, with unit deliveries up 35%. Gross margin rose to 86.4%, and operating loss declined 24%, supported by expanded insurance coverage from the new Category I CPT® code.
Cash was $7.1 million on March 31, 2026, plus $2.1 million raised afterward. NeurAxis highlighted new FDA clearances for IB-Stim, VA Federal Supply Schedule access, and pediatric guideline recommendations, broadening its addressable market.
NeurAxis (NYSE American: NRXS) will report summarized financial results for the first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026 before market open. The company also scheduled a conference call the same day at 9:00 AM ET to review results, with webcast and replay details provided.
Dial-in numbers, webcast link, and replay access code are available for investors and analysts to listen live or access the replay.
NeurAxis (NYSE: NRXS) announced four additional medical policies for Percutaneous Electrical Nerve Field Stimulation (PENFS), adding approximately 1.25 million covered lives and extending access in West Virginia, New Hampshire, South Carolina, Virginia, and Florida.
The company cited Category I CPT code recognition, inclusion in clinical guidelines, FDA clearance of IB-Stim for specified DGBI indications in patients age 8+, and disclosed an auditor’s explanatory paragraph noting substantial doubt about going concern for fiscal year 2025.
NeurAxis (NYSE American: NRXS) declared a stock dividend on its Series B preferred stock on April 10, 2026. Holders of record as of April 21, 2026 will receive common stock based on accrued unpaid dividends divided by $2.38. The dividend is payable April 28, 2026.
Approximately 510,605 shares of common stock are expected to be issued; no fractional shares will be issued and fractional entitlements will be paid in cash calculated at $2.38 per fractional share.
NeurAxis (NYSE: NRXS) reported strong revenue growth and strategic commercial wins for 4Q25 and FY2025. Revenue grew 27% in 4Q25 to $968k and 33% for FY2025 to $3.6M. Operating loss widened to $1.7M in 4Q25 and $7.8M for FY2025; cash was $5.0M at year-end.
Key commercial milestones include a Category I CPT code effective Jan 1, 2026, a VA Federal Supply Schedule contract, expanded FDA clearance for IB-Stim for abdominal pain in patients 8+ years, and post-year At-The-Market proceeds of $2.6M.
NeurAxis (NYSE American: NRXS) will report summarized fourth quarter and full year 2025 results for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open.
The company will host a conference call and live webcast on March 19, 2026 at 9:00am ET; webcast and replay will be available in the Investor Relations section of the company's website. Participants can submit questions via the webcast portal or by emailing NRXS@lythampartners.com.
NeurAxis (NYSE American: NRXS) announced that an AMA Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now in effect as of Jan. 8, 2026. The code establishes a permanent, nationally recognized coding and billing pathway for NeurAxis’ IB-Stim therapy, signaling broad clinical acceptance and meeting AMA criteria for widespread utilization and clinical efficacy. Management said the code should improve payer alignment, reimbursement predictability, and scalability across health systems, potentially accelerating patient access and supporting long-term commercial growth. Management will present at the Lytham Partners Healthcare Investor Summit on Jan. 15, 2026.
NeurAxis (NYSE American: NRXS) announced new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (PENFS), adding approximately 45 million covered lives and bringing PENFS total national coverage to roughly 100 million covered lives.
The company’s FDA-cleared IB-Stim is approved for patients 8 years and older with functional abdominal pain related to IBS and functional dyspepsia. NeurAxis noted a Category I CPT code effective January 1, 2026, incorporation of PENFS into national clinical guidelines, and a strengthened balance sheet as positioning factors for expected revenue growth and margin expansion.
NeurAxis (NYSE American: NRXS) was awarded a Veterans Affairs Federal Supply Schedule contract effective December 1, 2025, listing its IB-Stim device as the first product on the FSS.
The award creates a federal commercial pathway into the VA health system, which serves nearly 7 million active patients annually. IB-Stim is an FDA-cleared percutaneous electrical nerve field stimulator for functional abdominal pain, approved for patients age 8 and older and described as the only FDA-cleared therapy for functional dyspepsia (FD). The company cited a Category I CPT code effective January 1, 2026 and said it will dedicate sales resources to VA channels to support commercialization into 2026.
NeurAxis (NYSE:NRXS) announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) in Michigan, adding approximately 566,000 covered lives and bringing estimated national coverage to about 55 million lives.
The policy gives roughly 82% of commercially insured pediatric beneficiaries in Michigan access to PENFS. IB-Stim is FDA-cleared for functional abdominal pain related to IBS and Functional Dyspepsia for patients aged 8+. A Category I CPT code becomes effective January 1, 2026, and management cites ongoing payer discussions and a strengthened balance sheet to support expected revenue growth.